Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Henning Willers, M.D.

Co-Author

This page shows the publications co-authored by Henning Willers and Lecia Sequist.
Connection Strength

1.815
  1. Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. Cell Rep. 2019 06 18; 27(12):3422-3432.e4.
    View in: PubMed
    Score: 0.211
  2. Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers. Oncologist. 2018 09; 23(9):1054-1062.
    View in: PubMed
    Score: 0.195
  3. Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res. 2017 04 15; 77(8):2018-2028.
    View in: PubMed
    Score: 0.179
  4. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. Oncologist. 2016 08; 21(8):964-73.
    View in: PubMed
    Score: 0.171
  5. Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy. J Thorac Oncol. 2015 Nov; 10(11):1601-7.
    View in: PubMed
    Score: 0.164
  6. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res. 2013 Oct 15; 73(20):6254-63.
    View in: PubMed
    Score: 0.141
  7. Detection of impaired homologous recombination repair in NSCLC cells and tissues. J Thorac Oncol. 2013 Mar; 8(3):279-86.
    View in: PubMed
    Score: 0.136
  8. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624.
    View in: PubMed
    Score: 0.124
  9. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist. 2011; 16(6):886-95.
    View in: PubMed
    Score: 0.121
  10. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010 Nov; 12(11):1193-9.
    View in: PubMed
    Score: 0.113
  11. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. JTO Clin Res Rep. 2021 Jan; 2(1):100124.
    View in: PubMed
    Score: 0.058
  12. Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period. Cancer Res. 2020 11 15; 80(22):5121-5133.
    View in: PubMed
    Score: 0.057
  13. Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. Oncologist. 2020 05; 25(5):431-437.
    View in: PubMed
    Score: 0.055
  14. Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. Cancer Res. 2019 07 15; 79(14):3776-3788.
    View in: PubMed
    Score: 0.052
  15. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol. 2015 Feb; 17(2):296-302.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.